LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Kodu・Aktsiate loetelu・MacroGenics Inc

MacroGenics Inc

Avatud

Sektor Tervishoid

3.69 -4.65

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.6

Max

3.87

Põhinäitajad
By Trading Economics
Sissetulek	-3.5M -56M
Müük	49M 58M
P/E Sektori keskmine	38.83 104.138
Aktsiakasum	-0.89
Kasumimarginaal	-96.273
Töötajad	339
EBITDA	-4.6M -54M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+84.5 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. nov 2024

Turustatistika
By TradingEconomics
Turukapital	3.8M 233M
Eelmine avamishind	8.34
Eelmine sulgemishind	3.69

Uudiste sentiment

By Acuity

73%

27%

345 / 390 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

3.34 / 3.9 Toetus ja vastupanu

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. nov 2024, 23:05 UTC

Peamised uudised

Fitch Affirms Australia's Sovereign AAA Rating, But Warns Of Mounting Budget Risks

3. nov 2024, 21:12 UTC

Tulu

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects -- Update

3. nov 2024, 20:59 UTC

Tulu

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects

3. nov 2024, 23:34 UTC

Peamised uudised

Stocks Poised for Lower Open -- Barrons.com

3. nov 2024, 23:16 UTC

Peamised uudised

Tulu

Berkshire Hathway Earnings Weren't as Bad as They Looked -- Barrons.com

3. nov 2024, 22:50 UTC

Omandamised, ülevõtmised, äriostud

Santos Says Working Interest in PNG LNG Now 39.9%

3. nov 2024, 22:50 UTC

Omandamised, ülevõtmised, äriostud

Santos Says Kumul to Assume $90 Million of Project Finance Debt Associated With Stake

3. nov 2024, 22:49 UTC

Omandamised, ülevõtmised, äriostud

Santos Says Final Payment Takes Total Cash Consideration to $602 Million

3. nov 2024, 22:49 UTC

Omandamised, ülevõtmised, äriostud

Santos Receives Final $241 Million Payment From Kumul

3. nov 2024, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Santos Completes Sale of 2.6% Interest in PNG LNG to Kumul Petroleum

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Deposits Increased 5% to A$674 Billion

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Loans Increased 4% to A$807 Billion

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Impairment Charges 7 Bps of Loans

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Operating Expenses A$10.94 Billion, Up 7% Excluding Notable Items

3. nov 2024, 20:36 UTC

Tulu

Westpac FY 2024 Non-Interest Income A$2.84 Billion, Down 15%

3. nov 2024, 20:35 UTC

Tulu

Westpac FY 2024 CET1 Level 2 Capital Ratio 12.5%, Up 11 Bps

3. nov 2024, 20:35 UTC

Tulu

Westpac Raises Share Buyback Program by A$1 Billion

3. nov 2024, 20:35 UTC

Tulu

Westpac Final Dividend A$0.76/Share

3. nov 2024, 20:33 UTC

Tulu

Westpac FY 2024 Net Interest Margin Down 1 Bps at 1.95%

3. nov 2024, 20:32 UTC

Tulu

Westpac FY 2024 Revenue A$21.59 Billion, Flat on FY 2023

3. nov 2024, 20:32 UTC

Tulu

Westpac FY Net Profit A$6.99 Billion, Down 3%

3. nov 2024, 18:09 UTC

Peamised uudised

Boeing Had a Big Week. This One Is Even Bigger. -- Barrons.com

3. nov 2024, 10:30 UTC

Peamised uudised

Fed Prepares Rate Cut Amid Economic Contradictions -- WSJ

3. nov 2024, 03:00 UTC

Peamised uudised

Disgraced Lebanese Central Banker Who Was a Fugitive Now Awaits His Fate -- WSJ

2. nov 2024, 13:53 UTC

Peamised uudised

Tulu

Omandamised, ülevõtmised, äriostud

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2. nov 2024, 13:44 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. nov 2024, 13:00 UTC

Peamised uudised

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2. nov 2024, 12:58 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. nov 2024, 12:48 UTC

Peamised uudised

Tulu

Omandamised, ülevõtmised, äriostud

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2. nov 2024, 12:32 UTC

Tulu

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

84.5% tõus

12 kuu keskmine prognoos

Keskmine 7.14 USD 84.5%

Kõrge 14 USD

Madal 4 USD

Põhineb 10 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi MacroGenics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.34 / 3.9Toetus ja vastupanu

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

345 / 390 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest MacroGenics Inc

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.